Efficacy and Safety of RelabotulinumtoxinA Liquid Botulinum Toxin in the Treatment of Lateral Canthal Lines: Results From the Phase 3 READY-2 Study
RelaBoNT-A (60 U) treatment provided statistically significant improvement of moderate-to-severe LCL. One-third of subjects reported onset within 1 day and improvements were maintained through Month 6. Treatment satisfaction was high. RelaBoNT-A was well tolerated.
Authors
- Shannon Humphrey (ORCID: https://orcid.org/0000-0002-7734-3146)
- Glynis Ablon (ORCID: https://orcid.org/0000-0001-7229-2717)
- Sarah Coquis-Knezek
- Theda C. Kontis
- Melanie D. Palm
- Lisa D. Grunebaum
- Jason K. Rivers (ORCID: https://orcid.org/0000-0002-0131-1607)
- Sue Ellen Cox (ORCID: https://orcid.org/0000-0003-0811-5681)
- David Bank
- Sherrif F. Ibrahim
- Mitchel P. Goldman
Institutions
- University of British Columbia (CA)
- Skin Cancer Foundation (US)
- WinnMed (US)
- Cosmetic Laser Dermatology (US)
- Galderma (United States) (US)
- Ablon Skin Institute and Research Center (US)
- Mayo Clinic in Florida (US)
- Center for Dermatology, Cosmetic & Laser Surgery (US)
Publication Details
- Journal
- Dermatologic Surgery
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1097/dss.0000000000004470
- Citations
- 4
- Primary Topic
- Botulinum Toxin and Related Neurological Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.48
Funders
- Galderma
- LEO Pharma
- Allergan